tag:blogger.com,1999:blog-1428969590789818099.post648545142935636555..comments2024-03-26T21:49:20.994+01:00Comments on Rheumatologe: Biosimilars after the EULAR 2013 Rheumatologehttp://www.blogger.com/profile/16169204718725630420noreply@blogger.comBlogger3125tag:blogger.com,1999:blog-1428969590789818099.post-10160760295038974302013-07-17T16:28:11.859+02:002013-07-17T16:28:11.859+02:00I’ve just deleted some spam from my blog and in th...I’ve just deleted some spam from my blog and in this process also deleted the comment above, which I luckily still had as email. But I also deleted my reply. So, if you’ve read another version now, that’s the reason why. It’s better to leave than to comment anonymously. The text below is a reconstruction, a palimpsest.<br /><br />EMA‘s ruling on Remicade biosimilar from Celltrion/Hospira and extrapolation of all Remicade's indications for Remsima might stem from putting pressure on MSD to reduce costs. I doubt that this will happen.<br />I would have liked to use Simponi exclusively IV, but MSD did not apply for another IV drug – that’s as far as the person from MSD has knowledge about these matters. The once a month strategy didn’t work out with the patients. At least with my patients. There some happy with long interval, but others are happy even at weekly intervals. And I have quite a lot of patients being very happy with Remicade at intervals of 15 to over 20 weeks. There might be a reason behind refiling Simponi IV, but I see more player emerging as well known drug companies endeavor on developing biosimilars.<br />Rheumatologehttps://www.blogger.com/profile/16169204718725630420noreply@blogger.comtag:blogger.com,1999:blog-1428969590789818099.post-80317444607925878502013-07-17T16:05:14.439+02:002013-07-17T16:05:14.439+02:00I've deleted my reply, too. Maybe someone has ...I've deleted my reply, too. Maybe someone has copied it, so it would be nice to send it back to me.Rheumatologehttps://www.blogger.com/profile/16169204718725630420noreply@blogger.comtag:blogger.com,1999:blog-1428969590789818099.post-70053814671268591942013-07-17T16:03:36.448+02:002013-07-17T16:03:36.448+02:00I removed by chance this valuable comment, which c...I removed by chance this valuable comment, which came anonymously.<br />Love you blog. What are your thoughts around the EMA ruling for the Remicade biosimilar from Celltrion/Hospira? I think it's interesting that the EMA acted so quickly with extrapolation of all Remicade's indications for Remsima.<br /><br />I wonder how MSD is going to react, especially with the refiling of Simponi IV. I was wondering what the point of the Simponi IV formulation was but i supposed it's to combat the biosimilars, similar to the strategy they tried to employ with Risperdal/Invega. Do you see Simponi IV being better for a particular patient type or as a play to combat biosimilars?<br /><br />Keep up the great work! <br />Rheumatologehttps://www.blogger.com/profile/16169204718725630420noreply@blogger.com